Company intelligence / Profile preview

SymTrend

Cambridge, Massachusetts, United Statesdanbricklin.com ↗

Ownership: Private
Development stage: Commercial

Overview

SymTrend develops a mobile/web-based digital health platform designed to help manage chronic conditions such as vascular dementia risk factors and neurodevelopmental disorders. The company has conducted at least three clinical trials involving its technology. It also appears to have been involved in the development or testing of combination drug products targeting brain injuries but with no approved drugs as of May 2025. Its main value proposition is improving adherence to lifestyle interventions through digital tracking and feedback.

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceNon-pharmacological therapyDigital therapeutic (mobile/web system for disease management)
Industry: Biotech

Drug pipeline

4 assets

SymTrend Standard

Commercial

Indications: Behavioral health, Special education

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships disclosed; some academic collaborations suggested by grant activity.

Beyond the preview

Go deeper on SymTrend.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SymTrend.

Explore the full profile